395 related articles for article (PubMed ID: 3128400)
1. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
2. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.
Weiner LM; Steplewski Z; Koprowski H; Litwin S; Comis RL
Cancer Res; 1988 Feb; 48(4):1042-6. PubMed ID: 3123051
[TBL] [Abstract][Full Text] [Related]
3. Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma.
Weiner LM; Steplewski Z; Koprowski H; Sears HF; Litwin S; Comis RL
Hybridoma; 1986 Jul; 5 Suppl 1():S65-77. PubMed ID: 3091476
[TBL] [Abstract][Full Text] [Related]
4. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
6. Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy.
Blottière HM; Steplewski Z; Herlyn D; Douillard JY
Hum Antibodies Hybridomas; 1991 Jan; 2(1):16-25. PubMed ID: 1908336
[TBL] [Abstract][Full Text] [Related]
7. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L
Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902
[TBL] [Abstract][Full Text] [Related]
8. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
[TBL] [Abstract][Full Text] [Related]
10. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
[TBL] [Abstract][Full Text] [Related]
11. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
[TBL] [Abstract][Full Text] [Related]
12. Antibody-mediated erythrolysis and erythrophagocytosis by human monocytes, macrophages and activated macrophages. Evidence for distinction between involvement of high-affinity and low-affinity receptors for IgG by using different erythroid target cells.
Rüegg SJ; Jungi TW
Immunology; 1988 Mar; 63(3):513-20. PubMed ID: 2965100
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of CO17-1A monoclonal antibody.
Lobuglio AF; Saleh M; Peterson L; Wheeler R; Carrano R; Huster W; Khazaeli MB
Hybridoma; 1986 Jul; 5 Suppl 1():S117-23. PubMed ID: 3488950
[TBL] [Abstract][Full Text] [Related]
15. Anti-idiotypic antibodies to monoclonal antibody CO17-1A.
Herlyn D; Sears H; Iliopoulos D; Lubeck M; Douillard JY; Sindelar W; Tempero M; Mellstedt H; Maher M; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S51-8. PubMed ID: 3488951
[TBL] [Abstract][Full Text] [Related]
16. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
17. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2.
Morgan AC; Sullivan W; Graves S; Woodhouse CS
Cancer Res; 1989 May; 49(10):2773-6. PubMed ID: 2785437
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
Lee YC; Washburn LC; Sun TT; Byrd BL; Crook JE; Holloway EC; Steplewski Z
Cancer Res; 1990 Aug; 50(15):4546-51. PubMed ID: 2164441
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
Saleh MN; Khazaeli MB; Grizzle WE; Wheeler RH; Lawson S; Liu T; Russel C; Meredith R; Schlom J; LoBuglio AF
Cancer Res; 1993 Oct; 53(19):4555-62. PubMed ID: 8402627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
